PTPN22 R620W polymorphism in the ANCA-associated vasculitides.

OBJECTIVES PTPN22 is involved in T-cell activation and its R620W single-nucleotide polymorphism (SNP) has been shown to predispose to different autoimmune diseases. The aims of this study were to investigate the role of the PTPN22 R620W SNP in conferring susceptibility to the ANCA-associated vasculitides (AAVs), and to explore potential associations between the PTPN22 genotype and the disease manifestations. METHODS PTPN22 R620W SNP was genotyped in a cohort of 344 AAV patients [143 with granulomatosis with polyangiitis (Wegener's) (GPA), 102 with microscopic polyangiitis (MPA) and 99 with Churg-Strauss syndrome (CSS)] and in 945 healthy controls. RESULTS The frequency of the minor allele (620W) was significantly higher in GPA patients than in controls [P = 0.005, χ(2 )= 7.858, odds ratio (OR) = 1.91], while no statistically significant association was found with MPA or CSS. Among GPA patients, the 620W allele was particularly enriched in ANCA-positive patients as compared with controls (P = 0.00012, χ(2 )= 14.73, OR = 2.31); a particularly marked association was also found with ENT involvement (P = 0.0071, χ(2 )= 7.258, OR = 1.98), lung involvement (P = 0.0060, χ(2 )= 7.541, OR = 2.07) and skin manifestations of all kinds (P = 0.000047, χ(2 )= 16.567, OR = 3.73). CONCLUSION The PTPN22 620W allele confers susceptibility to the development of GPA (but not of MPA or CSS), and particularly of its ANCA-positive subset.

[1]  D A Bloch,et al.  The American College of Rheumatology 1990 criteria for the classification of Churg-Strauss syndrome (allergic granulomatosis and angiitis). , 2010, Arthritis and rheumatism.

[2]  D A Bloch,et al.  The American College of Rheumatology 1990 criteria for the classification of Wegener's granulomatosis. , 2010, Arthritis and rheumatism.

[3]  P. Merkel,et al.  Rituximab versus cyclophosphamide for ANCA-associated vasculitis. , 2010, The New England journal of medicine.

[4]  Kenneth G. C. Smith,et al.  The contribution of genetic variation and infection to the pathogenesis of ANCA-associated systemic vasculitis , 2010, Arthritis research & therapy.

[5]  J. Epplen,et al.  Recent progress in the genetics of Wegener's granulomatosis and Churg–Strauss syndrome , 2010, Current opinion in rheumatology.

[6]  Kenneth G. C. Smith,et al.  Confirmation of the genetic association of CTLA4 and PTPN22 with ANCA-associated vasculitis , 2009, BMC Medical Genetics.

[7]  A. Chan,et al.  Novel association of the CD226 (DNAM-1) Gly307Ser polymorphism in Wegener's granulomatosis and confirmation for multiple sclerosis in German patients , 2009, Genes and Immunity.

[8]  V. Kuchroo,et al.  Faculty Opinions recommendation of Cutting edge: the PTPN22 allelic variant associated with autoimmunity impairs B cell signaling. , 2009 .

[9]  Judy H. Cho,et al.  Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease , 2008, Nature Genetics.

[10]  R. Spritz,et al.  PTPN22 is genetically associated with risk of generalized vitiligo, but CTLA4 is not. , 2008, The Journal of investigative dermatology.

[11]  F. Moosig,et al.  Functionally relevant variations of the interleukin-10 gene associated with antineutrophil cytoplasmic antibody-negative Churg-Strauss syndrome, but not with Wegener's granulomatosis. , 2008, Arthritis and rheumatism.

[12]  T. Mustelin,et al.  Protein tyrosine phosphatases in autoimmunity. , 2008, Annual Review of Immunology.

[13]  C. Ribi,et al.  Treatment of Churg-Strauss syndrome without poor-prognosis factors: a multicenter, prospective, randomized, open-label study of seventy-two patients. , 2008, Arthritis and rheumatism.

[14]  E. Edell,et al.  Airway involvement in Wegener's granulomatosis. , 2007, Rheumatic diseases clinics of North America.

[15]  A. Andriulli,et al.  Evaluating the role of the genetic variations of PTPN22, NFKB1, and FcGRIIIA genes in inflammatory bowel disease: A meta‐analysis , 2007, Inflammatory bowel diseases.

[16]  U. Maggiore,et al.  HLA-DRB4 as a genetic risk factor for Churg-Strauss syndrome. , 2007, Arthritis and rheumatism.

[17]  J. Barrett,et al.  Association of PTPN22 haplotypes with Graves' disease. , 2007, The Journal of clinical endocrinology and metabolism.

[18]  B. Prum,et al.  Linkage proof for PTPN22, a rheumatoid arthritis susceptibility gene and a human autoimmunity gene , 2007, Proceedings of the National Academy of Sciences.

[19]  C. Kallenberg.  Antineutrophil cytoplasmic autoantibody-associated small-vessel vasculitis , 2007, Current opinion in rheumatology.

[20]  C. Kallenberg,et al.  Mechanisms of Disease: pathogenesis and treatment of ANCA-associated vasculitides , 2006, Nature Clinical Practice Rheumatology.

[21]  D. Scott,et al.  Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies , 2006, Annals of the rheumatic diseases.

[22]  P. Gregersen,et al.  PTPN22: setting thresholds for autoimmunity. , 2006, Seminars in immunology.

[23]  S. Frank,et al.  Evaluation of the genetic association of the PTPN22 R620W polymorphism in familial and sporadic systemic lupus erythematosus. , 2006, Arthritis and rheumatism.

[24]  U. Maggiore,et al.  Outcome and prognostic factors during the course of primary small-vessel vasculitides. , 2006, The Journal of rheumatology.

[25]  M. Pierer,et al.  Association of PTPN22 1858 single-nucleotide polymorphism with rheumatoid arthritis in a German cohort: higher frequency of the risk allele in male compared to female patients , 2006, Arthritis research & therapy.

[26]  R. Luqmani,et al.  The role of biologic therapies in the management of systemic vasculitis. , 2006, Autoimmunity reviews.

[27]  A. Hinks,et al.  The association of PTPN22 with rheumatoid arthritis and juvenile idiopathic arthritis. , 2006, Rheumatology.

[28]  J. Jais,et al.  Association of the PTPN22*R620W polymorphism with autoimmune myasthenia gravis , 2006, Annals of neurology.

[29]  P. Gregersen.  Gaining insight into PTPN22 and autoimmunity , 2005, Nature Genetics.

[30]  J. Epplen,et al.  The PTPN22 620W allele is a risk factor for Wegener's granulomatosis. , 2005, Arthritis and rheumatism.

[31]  Nunzio Bottini,et al.  Autoimmune-associated lymphoid tyrosine phosphatase is a gain-of-function variant , 2005, Nature Genetics.

[32]  J. Heward,et al.  HLA, CTLA-4 and PTPN22: the shared genetic master-key to autoimmunity? , 2005, Expert Reviews in Molecular Medicine.

[33]  Steven J. Schrodi,et al.  PTPN22 genetic variation: evidence for multiple variants associated with rheumatoid arthritis. , 2005, American journal of human genetics.

[34]  Laura Pavone,et al.  Prevalence and clinical significance of antineutrophil cytoplasmic antibodies in Churg-Strauss syndrome. , 2005, Arthritis and rheumatism.

[35]  M. Feldmann,et al.  Molecular therapeutic targets in rheumatoid arthritis , 2005, Expert Reviews in Molecular Medicine.

[36]  R. Cantor,et al.  Association analysis of the R620W polymorphism of protein tyrosine phosphatase PTPN22 in systemic lupus erythematosus families: increased T allele frequency in systemic lupus erythematosus patients with autoimmune thyroid disease. , 2005, Arthritis and rheumatism.

[37]  Wendy Thomson,et al.  Association between the PTPN22 gene and rheumatoid arthritis and juvenile idiopathic arthritis in a UK population: further support that PTPN22 is an autoimmunity gene. , 2005, Arthritis and rheumatism.

[38]  K. Boberg,et al.  Association analysis of the 1858C>T polymorphism in the PTPN22 gene in juvenile idiopathic arthritis and other autoimmune diseases , 2005, Genes and Immunity.

[39]  Steven J. Schrodi,et al.  A missense single-nucleotide polymorphism in a gene encoding a protein tyrosine phosphatase (PTPN22) is associated with rheumatoid arthritis. , 2004, American journal of human genetics.

[40]  Nunzio Bottini,et al.  A functional variant of lymphoid tyrosine phosphatase is associated with type I diabetes , 2004, Nature Genetics.

[41]  L. Diehl,et al.  PEST Domain-Enriched Tyrosine Phosphatase (PEP) Regulation of Effector/Memory T Cells , 2004, Science.

[42]  D. Scott,et al.  Are environmental factors important in primary systemic vasculitis? A case-control study. , 2003, Arthritis and rheumatism.

[43]  F. Moosig,et al.  Peripheral Blood and Granuloma CD4+CD28− T Cells Are a Major Source of Interferon-γ and Tumor Necrosis Factor-α in Wegener’s Granulomatosis , 2002 .

[44]  David Steven Scott,et al.  Systemic vasculitis: epidemiology, classification and environmental factors , 2000, Annals of the rheumatic diseases.

[45]  Y. Zhou,et al.  Polymorphisms in CTLA-4 but not tumor necrosis factor-alpha or interleukin 1beta genes are associated with Wegener's granulomatosis. , 2000, The Journal of rheumatology.

[46]  V. Cottin,et al.  Churg-Strauss Syndrome , 2004, Seminars in respiratory and critical care medicine.

[47]  R J Falk,et al.  Nomenclature of systemic vasculitides. Proposal of an international consensus conference. , 1994, Arthritis and rheumatism.

[48]  Y H Lee,et al.  The PTPN22 C1858T functional polymorphism and autoimmune diseases--a meta-analysis. , 2007, Rheumatology.

[49]  P. Lamprecht,et al.  Current knowledge on cellular interactions in the WG-granuloma. , 2007, Clinical and experimental rheumatology.

[50]  Javier Martín,et al.  Association of a functional single-nucleotide polymorphism of PTPN22, encoding lymphoid protein phosphatase, with rheumatoid arthritis and systemic lupus erythematosus. , 2005, Arthritis and rheumatism.

[51]  F. Moosig,et al.  Peripheral blood and granuloma CD4(+)CD28(-) T cells are a major source of interferon-gamma and tumor necrosis factor-alpha in Wegener's granulomatosis. , 2002, The American journal of pathology.